Tetrazole compounds as thyroid receptor ligands

Abstract

The present invention relates to tetrazole compounds of Formula 1, stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, and pharmaceutically acceptable salts of the prodrugs. The invention also relates to compositions comprising the tetrazole compounds and to methods of treating obesity, diabetes, atherosclerosis, hypertension, coronary heart disease, hypercholesterolemia, hyperlipidemia, thyroid disease, thyroid cancer, hypothyroidism, depression, glaucoma, cardiac arrhythmias, congestive heart failure, and osteoporosis using the tetrazole compounds.

What is claimed is:  
     
         1 . A compound of Formula I  
       
         
           
           
               
               
           
         
         or a stereoisomer, pharmaceutically acceptable salt or prodrugs thereof, or a pharmaceutically acceptable salt of the prodrug, wherein: 
 W is O, S, SO, SO 2 , CH 2 , CF 2 , CHF, C(═O), CH(OH), NR a , or  
                     
 X is O, CH 2 , CH 2 CH 2 , S, SO, SO 2 , CH 2 NR a , NR a , or a bond;  
 each R a  is independently hydrogen, C 1 -C 6 alkyl, or C 1 -C 6 alkyl substituted with one substituent selected from C 3 -C 6 cycloalkyl or methoxy;  
 R 1 , R 2 , R 3  and R 6  are independently hydrogen, halogen, C 1 -C 8 alkyl, —CF 3 , —OCF 3 , —OC 1 -C 8 alkyl, or —CN;  
 R 4  is hydrogen, C 1 -C 12 alkyl, [C 1 -C 12 alkyl that is substituted with from one to three substituents independently selected from Group V], C 2 -C 12  alkenyl, C 2 -C 12  alkynyl, halogen, —CN, —OR b , —SR c , —S(═O)R c , —S(═O) 2 R c , aryl, heteroaryl, C 3 -C 10 cycloalkyl, heterocycloalkyl, —S(═O) 2 NR c R d , —C(═O)NR c R d , C(═O)OR c , —NR a C(═O)R d , —NR a C(═O)NR c R d , —NR a S(═O) 2 R d , —NR a R d , —C(═O)R c ,  
 or R 3  and R 4  may be taken together with the carbon atoms to which they are attached to form an unsubstituted or substituted carbocyclic ring of formula —(CH 2 ) i — or an unsubstituted or substituted heterocyclic ring selected from the group consisting of —Q—(CH 2 ) j — and —(CH 2 ) k —Q—(CH 2 ) i — wherein Q is O, S or NR a ; i is 3, 4, 5, 6 or 7; j is 2, 3, 4, 5, or 6; k and I are each independently 1, 2, 3, 4, or 5, and any substituents up to four are selected from C 1 -C 4 alkyl, —OR b , oxo, —CN, phenyl, or  
 R b  is hydrogen, C 1 -C 12 alkyl, [C 1 -C 12 alkyl substituted with one to three substituents independently selected from Group V], aryl, heteroaryl, C 3 -C 10  cycloalkyl, heterocycloalkyl, —C(═O)NR c R d , or  
 R c  and R d  are each independently selected from hydrogen, C 1 -C 12 alkyl, [C 1 -C 12 alkyl substituted with one to three substituents independently selected from Group VI], C 2 -C 12 alkenyl, C 2 -C 12 alkynyl, aryl, heteroaryl, C 3 -C 10  cycloalkyl, heterocycloalkyl,  
 or R c  and R d  may together along with the atom(s) to which they are attached form a 3-10 membered unsubstituted or substituted heterocyclic ring, which may contain a second heterogroup selected from O, NR e , or S, wherein any substitutents up to four are selected from C 1 -C 4 alkyl, —OR b , oxo, —CN, phenyl, or —NR a R g ;  
 R 5  is —OH, —OC 1 -C 6 alkyl, —OC(═O)R f , —F, —C(═O)OR c ,  
 or R 4  and R 5  may together with the atom(s) to which they are attached form a heterocyclic ring selected from the group consisting of —CR c ═CR a —NH—, —N═CR a —NH—, —CR c ═CR a —O—, —CR c ═CR a —S—, —CR c ═N—NH—, or —CR a ═CR a —CR a ═N—;  
 Group V is halogen, —CF 3 , —OCF 3 , hydroxy, oxo, C 1 -C 6 alkoxy, —CN, aryl, heteroaryl, C 3 -C 10  cycloalkyl, heterocycloalkyl, —SR f , —S(═O)R f ,  
 —S(═O) 2 R f , [—S(═O) 2 NR a R f , wherein R a  and R f  may together along with the atom(s) to which they are attached form a 3-8 membered heterocyclic ring, which may contain a second heterogroup selected from O, NR e  or S], —NR a R g , or [—C(═O)NR a R f , wherein R a  and R f  may together along with the atom(s) to which they are attached form a 3-8 membered heterocyclic ring, which may contain a second heterogroup selected from O, NR e  or S];  
 Group VI is halogen, hydroxy, oxo, C 1 -C 6 alkoxy, aryl, heteroaryl, C 3 -C 8 cycloalkyl, heterocycloalkyl, —CN, or —OCF 3 ;  
 R e  is hydrogen, —CN, C 1 -C 10  alkyl, [C 1 -C 10  alkyl substituted with one to three substitutents independently selected from Group V], C 2 -C 10 alkenyl, C 2 -C 10 alkoxy, C 3 -C 10 cycloalkyl, aryl, heteroaryl, —C(═O)R f , —C(═O)OR f , —C(═O)NR a R f —S(═O) 2 NR a R f , or —S(═O) 2 R f ;  
 R f  is hydrogen, C 1 -C 10 alkyl, [C 1 -C 10 alkyl substituted with from one to three substituents selected from Group VI], C 2 -C 10 alkenyl, C 2 -C 10 alkoxy, C 3 -C 10 cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; and  
 R g  is hydrogen, C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, C 2 -C 6  alkenyl, aryl, —C(═O)R f , —C(═O)OR f , —C(═O)NR a R f , or —S(═O) 2 R f , provided that R 1  and R 2 are not both hydrogen, further provided that when X is CH 2 , W is NR a , R 3  is hydrogen and R 5  is —OH, then R 6  and R 4  are not both —C(CH 3 ) 3 , further provided that when X is CH 2  or CH 2 CH 2 , W is O, and R 3  and R 6  are hydrogen, then R 4 is not halogen, —CF 3 , C 1 -C 6 alkyl or C 3 -C 7 cycloalkyl, and further provided that when R 3  and R 4  are hydrogen and W is O then R 6  is not halogen, —CF 3 , C 1 -C 6 alkyl or C 3 -C 7 cycloalkyl.  
 
       
     
     
         2 . A compound of  claim 1  wherein W is O.  
     
     
         3 . A compound of  claim 1  wherein X is a bond, NH, or CH 2 .  
     
     
         4 . A compound of  claim 1  wherein R 1 and R 2  are independently C 1 -C 8 alkyl, halogen, or —CN.  
     
     
         5 . A compound of  claim 4  wherein the C 1 -C 8 alkyl groups are —CH 3  and the halogens are chlorine, bromine, or iodine.  
     
     
         6 . A compound of  claim 1  wherein R 6  is hydrogen.  
     
     
         7 . A compound of  claim 1  wherein R 5  is —OH, —OC(═O)R f , or —F.  
     
     
         8 . A compound of  claim 1  wherein 
 W is O;  
 X is a bond, NH, or CH 2 ;  
 R 1 and R 2  are independently —CH 3 , Cl, Br, or I;  
 R 6  is hydrogen;  
 R 5  is —OH;  
 R 3  is hydrogen, halogen, C 1 -C 6 alkyl, —CF 3 , —OCF 3 , —OC 1 -C 6 alkyl, or —CN; and  
 R 4  is hydrogen, C 1 -C 12 alkyl, [C 1 -C 12 alkyl that is substituted with from one to three substituents independently selected from Group V], C 2 -C 12  alkenyl, C 2 -C 12  alkynyl, halogen, —CN, —OR b , —SR c , —S(═O)R c , —S(═O) 2 R c , aryl, heteroaryl, C 3 -C 10  cycloalkyl, heterocycloalkyl, —S(═O) 2 NR c R d , —C(═O)NR c R d , —C(═O)OR c , —NR a C(═O)R d , —NR a C(═O)NR c R d , —NR a S(═O) 2 R d , —NR a R d , wherein aryl is phenyl or naphthyl either unsubstituted or substituted with from one to four substituents selected from halogen, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, —OCF 3 , —CN, —SR f , —S(═O)R f , —S(═O) 2 R f , C 3 -C 6 cycloalkyl, —S(═O) 2 NR a R f , —NR a R g , —C(═O)NR a R f , —OH, or C 1 -C 4 perfluoroalkyl; wherein heteroaryl is an unsubstituted, monosubstituted or disubstituted five or six membered aromatic ring having from 1 to 3 heteroatoms independently selected from O, N, or S, and wherein any substituents are selected from halogen, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, —CF 3 , —OH, —NR a R g , —CO 2 R f , or form a fused benzo group; and heterocycloalkyl is either unsubstituted or substituted with from one to four substituents selected from C 1 -C 4  alkyl, —OH, oxo, C 1 -C 4 alkoxy, —CN, phenyl, or —NR a R e .  
 or R 3  and R 4  may be taken together with the carbon atoms to which they are attached to form a carbocyclic ring of formula —(CH 2 ) i — or a heterocyclic ring selected from the group consisting of —Q—(CH 2 ) j — and —(CH 2 ) k —Q—(CH 2 ) l — wherein Q is O, S or NR a ; i is 3, 4, 5, 6 or 7; j is 2, 3, 4, 5, or 6; and k and I are each independently 2, 3, 4, 5, or 6.  
 
     
     
         10 . A compound of Formula I  
       
         
           
           
               
               
           
         
         or a stereoisomer, pharmaceutically acceptable salt or prodrug thereof, or a pharmaceutically acceptable salt of the prodrug, wherein: 
 W is O;  
 X is a bond or NH;  
 R 1 and R 2  are independently halogen or C 1 -C 8 alkyl;  
 R 3  and R 6  are hydrogen;  
 R 5 is —OH;  
 R 4  is C 1 -C 8  alkyl, —S(═O) 2 NR c R d , —C(═O)NR c R d , or —S(═O) 2 R c , and  
 R c  and R d  are independently hydrogen, C 1 -C 1-2 alkyl, C 3 -C 10 cycloalkyl, aryl, heteroaryl, substituted cycloalkyl, heterocycloalkyl, aryl, heteroaryl, or R c  and R d  taken together with the nitrogen atom to which they are attached form a heterocycloalkyl ring or a substituted heterocycloalkyl ring.  
 
       
     
     
         11 . The compound: 
 4-[2,6-dimethyl-4-(2H-tetrazol-5-yl)-phenoxy]-2-isopropyl-phenol;    4-[2,6-dichloro-4-(1H-tetrazol-5-yl)-phenoxy]-2-isopropyl-phenol;    4-[2,6-dichloro-4-(2H-tetrazol-5-yl)-phenoxy]-2-(pyrrolidine-1-sulfonyl)-phenol;    4-[2,6-dichloro-4-(2H-tetrazol-5-yl)-phenoxy]-2-(piperidine-1-sulfonyl)-phenol;    4-[2,6-dichloro-4-(2H-tetrazol-5-yl)-phenoxy]-2-(3,3-dimethyl-piperidine-1-sulfonyl)-phenol;    N-cyclopropyl-5-[2,6-dichloro-4-(2H-tetrazol-5-yl)-phenoxy]-2-hydroxy-benzenesulfonamide;    5-[2,6-dichloro-4-(2H-tetrazol-5-yl)-phenoxy]-2-hydroxy-N,N-dimethyl-benzenesulfonamide;    {5-[2,6-dichloro-4-(1H-tetrazol-5-yl)-phenoxy]-2-hydroxy-phenyl}-piperidin-1-yl-methanone;    N-cyclobutyl-5-[2,6-dichloro-4-(1H-tetrazol-5-yl)-phenoxy]-2-hydroxy-benzamide;    N-cyclohexyl-5-[2,6-dichloro-4-(1H-tetrazol-5-yl)-phenoxy]-2-hydroxy-benzamide; or a stereoisomer, pharmaceutically acceptable salt or prodrug thereof, or a pharmaceutically acceptable salt of the prodrug.    
     
     
         12 . The compound: 
 {5-[2,6-dichloro-4-(1H-tetrazol-5-yl)-phenoxy]-2-hydroxy-phenyl}-pyrrolidin-1-yl-methanone;    N-bicyclo[2.2.1]hept-2-yl-5-[2,6-dichloro-4-(1H-tetrazol-5-yl)-phenoxy]-2-hydroxy-benzamide;    4-[2,6-dimethyl-4-(1H-tetrazol-5-ylamino)-phenoxy]-2-isopropyl-phenol;    5-[2-chloro-6-methyl-4-(1H-tetrazol-5-ylamino)-phenoxy]-N-cyclopropyl-2-hydroxy-benzenesulfonamide;    N-cyclopropyl-5-[2,6-dichloro-4-(1H-tetrazol-5-ylamino)-phenoxy]-2-hydroxy-benzenesulfonamide;    N-cyclobutyl-5-[2,6-dimethyl-4-(1H-tetrazol-5-ylamino)-phenoxy]-2-hydroxy-N-methyl-benzamide;    2-cyclopropylmethanesulfonyl-4-[2,6-dimethyl-4-(1H-tetrazol-5-ylamino)-phenoxy]-phenol; or a stereoisomer, pharmaceutically acceptable salt or prodrug thereof, or a pharmaceutically acceptable salt of the prodrug.    
     
     
         13 . The compound: 
 2-cyclobutylmethanesulfonyl-4-[2,6-dimethyl-4-(2H-tetrazol-5-ylamino)-phenoxy]-phenol;    2-cyclobutylmethanesulfonyl-4-[2,6-dichlorol-4-(2H-tetrazol-5-ylamino)-phenoxy]-phenol;    4-[2-chloro-6-methyl-4-(2H-tetrazol-5-ylamino)-phenoxy]-2-cyclobutylmethanesulfonyl-phenol;    2-cyclopentylmethanesulfonyl-4-[2,6-dimethyl-4-(2H-tetrazol-5-ylamino)-phenoxy]-phenol;    2-cyclopentylmethanesulfonyl-4-[2,6-dichlorol-4-(2H-tetrazol-5-ylamino)-phenoxy]-phenol;    4-[2-chloro-6-methyl-4-(2H-tetrazol-5-ylamino)-phenoxy]-2-cyclopentylmethanesulfonyl-phenol;    2-cyclohexylmethanesulfonyl-4-[2,6-dimethyl-4-(2H-tetrazol-5-ylamino)-phenoxy]-phenol;    2-cyclohexylmethanesulfonyl-4-[2,6-dichlorol-4-(2H-tetrazol-5-ylamino)-phenoxy]-phenol;    4-[2-chloro-6-methyl-4-(2H-tetrazol-5-ylamino)-phenoxy]-2-cyclohexylmethanesulfonyl-phenol;    4-[2,6-dimethyl-4-(2H-tetrazol-5-ylamino)-phenoxy]-2-(4-fluoro-benzenesulfonyl)-phenol;    4-[2,6-dichloro-4-(2H-tetrazol-5-ylamino)-phenoxy]-2-(4-fluoro-benzenesulfonyl)-phenol;    4-[2-chloro-6-methyl-4-(2H-tetrazol-5-ylamino)-phenoxy]-2-(4-fluoro-benzenesulfonyl)-phenol,    5-[2,6-dichloro-4-(2H-tetrazol-5-ylamino)-phenoxy]-2-hydroxy-N-methyl-benzamide;    N-butyl-5-[2,6-dichloro-4-(2H-tetrazol-5-ylamino)-phenoxy]-2-hydroxy-benzamide;    5-[2,6-dichloro-4-(2H-tetrazol-5-ylamino)-phenoxy]-2-hydroxy-N-isopropyl-benzamide;    5-[2,6-dichloro-4-(2H-tetrazol-5-ylamino)-phenoxy]-N-heptyl-2-hydroxy-benzamide;    5-[2,6-dichloro-4-(2H-tetrazol-5-ylamino)-phenoxy]-2-hydroxy-N-nonylbenzamide;    5-[2,6-dichloro-4-(2H-tetrazol-5-ylamino)-phenoxy]-N-(4-fluoro-phenyl)-2-hydroxy-benzamide;    N-cyclopentyl-5-[2,6-dichloro-4-(2H-tetrazol-5-ylamino)-phenoxy]-2-hydroxy-benzamide;    N-cyclohexyl-5-[2,6-dichloro-4-(2H-tetraol-5-ylamino)-phenoxy]-2-hydroxy-benzamide;    N-cycloheptyl-5-[2,6-dichloro-4-(2H-tetrazol-5-ylamino)-phenoxy]-2-hydroxy-benzamide;    N-cyclooctyl-5-[2,6-dichloro-4-(2H-tetrazol-5-ylamino)-phenoxy]-2-hydroxy-benzamide;    5-[2,6-dichloro-4-(2H-tetrazol-5-ylamino)-phenoxy]-2-hydroxy-N-(11-isopropyl-2-methyl-propyl)-benzamide;    N-cyclohexylmethyl-5-[2,6-dichloro-4-(2H-tetrazol-5-ylamino)-phenoxy]-2-hydroxy-benzamide;    N—(R-1-cyclohexyl-ethyl)-5-[2,6-dichloro-4-(2H-tetrazol-5-ylamino)-phenoxy]-2-hydroxy-benzamide;    N—(S-1-cyclohexyl-ethyl)-5-[2,6-dichloro-4-(1H-tetrazol-5-ylamino)-phenoxy]-2-hydroxy-benzamide;    N-cyclopentyl-5-[2,6-dichloro-4-(2H-tetrazol-5-ylamino)-phenoxy]-2-hydroxy-N-methyl-benzamide;    N-cyclohexyl-5-[2,6-dichloro-4-(2H-tetrazol-5-ylamino)-phenoxy]-2-hydroxy-N-methyl-benzamide;    N-cycloheptyl-5-[2,6-dichloro-4-(2H-tetrazol-5-ylamino)-phenoxy]-2-hydroxy-N-methyl-benzamide;    N-cyclooctyl-5-[2,6-dichloro-4-(2H-tetrazol-5-ylamino)-phenoxy]-2-hydroxy-N-methyl-benzamide;    5-[2,6-dichloro-4-(2H-tetrazol-5-ylamino)-phenoxy]-2-hydroxy-N-(1-isopropyl-2-methyl-propyl)-N-methyl-benzamide;    N-cyclohexylmethyl-5-[2,6-dichloro-4-(2H-tetrazol-5-ylamino)-phenoxy]-2-hydroxy-N-methyl-benzamide;    N—(R-1-cyclohexyl-ethyl)-5-[2,6-dichloro-4-(2H-tetrazol-5-ylamino)-phenoxy]-2-hydroxy-N-methyl-benzamide;    N—(S-1-cyclohexyl-ethyl)-5-[2,6-dichloro-4-(1H-tetrazol-5-ylamino)-phenoxy]-2-hydroxy-N-methyl-benzamide, or a stereoisomer, pharmaceutically acceptable salt or prodrug thereof, or a pharmaceutically acceptable salt of the prodrug.    
     
     
         14 . A method of treating diabetes, the method comprising the step of administering to a patient having or at risk of having diabetes, a therapeutically effective amount of a compound of  claim 1 , or a stereoisomer, pharmaceutically acceptable salt or prodrug thereof, or a pharmaceutically acceptable salt of the prodrug.  
     
     
         15 . The method of  claim 14  wherein the diabetes is Type I diabetes.  
     
     
         16 . The method of  claim 14  wherein the diabetes is Type II diabetes.  
     
     
         17 . A method of treating atherosclerosis, the method comprising the step of administering to a patient having or at risk of having atherosclerosis, a therapeutically effective amount of a compound of  claim 1 , or a stereoisomer, pharmaceutically acceptable salt or prodrug thereof, or a pharmaceutically acceptable salt of the prodrug.  
     
     
         18 . A method of treating hypertension, the method comprising the step of administering to a patient having or at risk of having hypertension, a therapeutically effective amount of a compound of  claim 1 , or a stereoisomer, pharmaceutically acceptable salt or prodrug thereof, or a pharmaceutically acceptable salt of the prodrug.  
     
     
         19 . A method of treating coronary heart disease, the method comprising the step of administering to a patient having or at risk of having coronary heart disease, a therapeutically effective amount of a compound of  claim 1 , or a stereoisomer, pharmaceutically acceptable salt or prodrug thereof, or a pharmaceutically acceptable salt of the prodrug.  
     
     
         20 . A method of treating hypercholesterolemia, the method comprising the step of administering to a patient having or at risk of having hypercholesterolemia, a therapeutically effective amount of a compound of  claim 1 , or a stereoisomer, pharmaceutically acceptable salt or prodrug thereof, or a pharmaceutically acceptable salt of the prodrug.  
     
     
         21 . A method of treating hyperlipidemia, the method comprising the step of administering to a patient having or at risk of having hyperlipidemia, a therapeutically effective amount of a compound of  claim 1 , or a stereoisomer, pharmaceutically acceptable salt or prodrug thereof, or a pharmaceutically acceptable salt of the prodrug.  
     
     
         22 . A method of treating thyroid disease, the method comprising the step of administering to a patient having or at risk of having thyroid disease, a therapeutically effective amount of a compound of  claim 1 , or a stereoisomer, pharmaceutically acceptable salt or prodrug thereof, or a pharmaceutically acceptable salt of the prodrug.  
     
     
         23 . A method of treating hypothyroidism, the method comprising the step of administering to a patient having or at risk of having hypothyroidism, a therapeutically effective amount of a compound of  claim 1 , or a stereoisomer, pharmaceutically acceptable salt or prodrug thereof, or a pharmaceutically acceptable salt of the prodrug.  
     
     
         24 . A method of treating depression, the method comprising the step of administering to a patient having or at risk of having depression, a therapeutically effective amount of a compound of  claim 1 , or a stereoisomer, pharmaceutically acceptable salt or prodrug thereof, or a pharmaceutically acceptable salt of the prodrug.  
     
     
         25 . A method of treating obesity, the method comprising the step of administering to an obese patient or a patient at risk of becoming obese, a therapeutically effective amount of a compound of  claim 1 , or a stereoisomer, pharmaceutically acceptable salt or prodrug thereof, or a pharmaceutically acceptable salt of the prodrug.  
     
     
         26 . A method of treating osteoporosis, the method comprising the step of administering to a patient having or at risk of having osteoporosis, a therapeutically effective amount of a compound of  claim 1 , or a stereoisomer, pharmaceutically acceptable salt or prodrug thereof, or a pharmaceutically acceptable salt of the prodrug.  
     
     
         27 . A method of treating thyroid cancer, the method comprising the step of administering to a patient having or at risk of having thyroid cancer, a therapeutically effective amount of a compound of  claim 1 , or a stereoisomer, pharmaceutically acceptable salt or prodrug thereof, or a pharmaceutically acceptable salt of the prodrug.  
     
     
         28 . A method of treating glaucoma, the method comprising the step of administering to a patient having or at risk of having glaucoma, a therapeutically effective amount of a compound of  claim 1 , or a stereoisomer, pharmaceutically acceptable salt or prodrug thereof, or a pharmaceutically acceptable salt of the prodrug.  
     
     
         29 . A method of treating cardiac arrhythmias, the method comprising the step of administering to a patient having or at risk of having cardiac arrhythmias, a therapeutically effective amount of a compound of  claim 1 , or a stereoisomer, pharmaceutically acceptable salt or prodrug thereof, or a pharmaceutically acceptable salt of the prodrug.  
     
     
         30 . A method of treating congestive heart failure, the method comprising the step of administering to a patient having or at risk of having congestive heart failure, a therapeutically effective amount of a compound of  claim 1 , or a stereoisomer, pharmaceutically acceptable salt or prodrug thereof, or a pharmaceutically acceptable salt of the prodrug.  
     
     
         31 . A method of increasing energy expenditure, the method comprising the step of administering to a patient who needs an energy expenditure increase a therapeutically effective amount of a compound of  claim 1 , or a stereoisomer, pharmaceutically acceptable salt or prodrug thereof, or a pharmaceutically acceptable salt of the prodrug.  
     
     
         32 . A pharmaceutical composition comprising a compound of  claim 1 , or a stereoisomer, pharmaceutically acceptable salt or prodrug thereof, or a pharmaceutically acceptable salt of the prodrug.  
     
     
         33 . A kit for the treatment of obesity, diabetes, atherosclerosis, hypertension, coronary heart disease, hypercholesterolemia, hyperlipidemia, thyroid disease, thyroid cancer, hypothyroidism, depression, glaucoma, cardiac arrhythmias, congestive heart failure, or osteoporosis, the kit comprising: 
 a) a first pharmaceutical composition comprising a compound of  claim 1 , or a stereoisomer, pharmaceutically acceptable salt or prodrug thereof, or a pharmaceutically acceptable salt of the prodrug;    b) a second pharmaceutical composition comprising an additional compound useful for the treatment of obesity, diabetes, atherosclerosis, hypertension, coronary heart disease, hypercholesterolemia, hyperlipidemia, thyroid disease, thyroid cancer, hypothyroidism, depression, glaucoma, cardiac arrhythmias, congestive heart failure, or osteoporosis; and    c) a container for containing the first and second compositions.    
     
     
         34 . A method of treating obesity, diabetes, atherosclerosis, hypertension, coronary heart disease, hypercholesterolemia, hyperlipidemia, thyroid disease, thyroid cancer, hypothyroidism, depression, glaucoma, cardiac arrhythmias, congestive heart failure, or osteoporosis, the method comprising the step of administering to an obese patient, a patient at risk of becoming obese, or a patient having or at risk of having diabetes, atherosclerosis, hypertension, coronary heart disease, hypercholesterolemia, hyperlipidemia, thyroid disease, thyroid cancer, hypothyroidism, depression, glaucoma, cardiac arrhythmias, congestive heart failure, or osteoporosis a therapeutically effective amount of 1) a compound of  claim 1 , or a stereoisomer, pharmaceutically acceptable salt or prodrug thereof, or a pharmaceutically acceptable salt of the prodrug and 2) an additional compound useful for treating obesity, diabetes, atherosclerosis, hypertension, coronary heart disease, hypercholesterolemia, hyperlipidemia, thyroid disease, thyroid cancer, hypothyroidism, depression, glaucoma, cardiac arrhythmias, congestive heart failure, or osteoporosis.  
     
     
         35 . A pharmaceutical composition comprising a compound of  claim 1 , or a stereoisomer, pharmaceutically acceptable salt or prodrug thereof, or a pharmaceutically acceptable salt of the prodrug, and an additional compound useful to treat obesity, diabetes, atherosclerosis, hypertension, coronary heart disease, hypercholesterolemia, hyperlipidemia, thyroid disease, thyroid cancer, hypothyroidism, depression, glaucoma, cardiac arrhythmias, congestive heart failure, or osteoporosis.